Stockreport

Virion Therapeutics Reports Positive First-in-human, First-in-class, Phase 1b Immunogenicity Data of VRON-0200, a Novel Checkpoint Modifier for HBV Functional Cure at EASL Congress [Yahoo!...

Ocean Biomedical, Inc.  (OCEA) 
PDF patients following a single, low dose, prime-only intramuscular injection of VRON-0200 VRON-0200 was well tolerated, with no serious adverse events (SAEs), study patie [Read more]